Quick Answer
SANGAMO THERAPEUTICS, INC reported Earnings Per Share Diluted of $0.44 (loss) per share for the year ending 2025.
- SANGAMO THERAPEUTICS, INC showed an increase of +10.2% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from SANGAMO THERAPEUTICS, INC's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $0.26 (loss) per share | Q3 2020: $0.01 (loss) per share | Q1 2021: $0.32 (loss) per share | Q2 2021: $0.33 (loss) per share | Q3 2021: $0.33 (loss) per share | Q1 2022: $0.30 (loss) per share | Q2 2022: $0.29 (loss) per share | Q3 2022: $0.34 (loss) per share | Q1 2023: $0.12 per share | Q2 2023: $0.66 (loss) per share | Q3 2023: $0.59 (loss) per share | Q1 2024: $0.27 (loss) per share | Q2 2024: $0.18 (loss) per share | Q3 2024: $0.04 per share | Q1 2025: $0.14 (loss) per share | Q2 2025: $0.08 (loss) per share | Q3 2025: $0.11 (loss) per share.
- Over the full 7 years of available data (2019 to 2025), SANGAMO THERAPEUTICS, INC's Earnings Per Share Diluted has grown by 48.2%.
- Historical annual values: Fiscal year 2025: $0.44 (loss) per share | Fiscal year 2024: $0.49 (loss) per share | Fiscal year 2023: $1.48 (loss) per share | Fiscal year 2022: $1.25 (loss) per share | Fiscal year 2021: $1.23 (loss) per share | Fiscal year 2020: $0.90 (loss) per share | Fiscal year 2019: $0.85 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: